Abraham DT, Low TH, Messina M, Jackson N, Gill A, Chou AS, Delbridge L, Learoyd D, Robinson BG, Sidhu S, Sywak M (2011) Medullary thyroid carcinoma: Long-term outcomes of surgical treatment. Ann Surg Oncol 18:219–225. https://doi.org/10.1245/s10434-010-1339-y
Pacini F, Castagna MG, Brilli L, Pentheroudakis G (2012) Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23:vii110–vii119. https://doi.org/10.1093/annonc/mds230
Van Veelen W, De Groot JWB, Acton DS, Hofstra RMW, Höppener JWM, Links TP, Lips CJM (2009) Medullary thyroid carcinoma and biomarkers: Past, present and future. J Intern Med 266:126–140. https://doi.org/10.1111/j.1365-2796.2009.02106.x
CAS Article PubMed Google Scholar
Schröder S, Böcker W, Baisch H, Bürk CG, Arps H, Meiners I, Kastendieck H, Heitz PU, Klöppel G (1988) Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content. Cancer 61:806–16.
Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH (2000) Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88:1139–48.
Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10-year follow-up study. J Clin Endocrinol Metab 93:682–687. https://doi.org/10.1210/jc.2007-1714
CAS Article PubMed Google Scholar
Moura MM, Cavaco BM, Leite V (2015) RAS proto-oncogene in medullary thyroid carcinoma. Endocr Relat Cancer 22:R235–R252. https://doi.org/10.1530/ERC-15-0070
CAS Article PubMed Google Scholar
Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, MacHens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG (2015) Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid 25:567–610. https://doi.org/10.1089/thy.2014.0335
Article PubMed PubMed Central Google Scholar
Park H, Park SY, Park J, Choe JH, Chung MK, Woo SY, Choi JY, Kim SW, Chung JH, Kim TH (2021) Prognostic Value of Preoperative Serum Calcitonin Levels for Predicting the Recurrence of Medullary Thyroid Carcinoma. Front Endocrinol (Lausanne) 12:1–8. https://doi.org/10.3389/fendo.2021.749973
Machens A, Ukkat J, Hauptmann S, Dralle H (2007) Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg 142:289–93; discussion 294 . https://doi.org/10.1001/archsurg.142.3.289
Censi S, Bertazza L, Piva I, Manso J, Benna C, Iacobone M, Mondin A, Plebani M, Faggian D, Galuppini F, Pennelli G, Barollo S, Mian C (2021) Serum miR-375 for Diagnostic and Prognostic Purposes in Medullary Thyroid Carcinoma. Front Endocrinol (Lausanne) 12:1–7. https://doi.org/10.3389/fendo.2021.647369
Erovic BM, Kim D, Cassol C, Goldstein DP, Irish JC, Asa SL, Mete O (2012) Prognostic and predictive markers in medullary thyroid carcinoma. Endocr Pathol 23:232–242. https://doi.org/10.1007/s12022-012-9225-8
CAS Article PubMed Google Scholar
Lloyd R, Osamura R, Kloppel G, Rosai J (2017) WHO Classification of Tumours of Endocrine Organs, 4th Ed. International Agency for Research on Cancer (IARC), Lyon
Who Classification of Tumours Editorial Board (2019) Digestive System Tumours, 5th Ed. International Agency for Research on Cancer (IARC), Lyon
Who Classification of Tumours Editorial Board (2021) Thoracic Tumours, 5th Ed. International Agency for Research on Cancer (IARC), Lyon
Ríos A, Rodríguez JM, Acosta JM, Balsalobre MD, Torregrosa N, Sola J, Pérez-Flores D, Parrilla P (2010) Prognostic value of histological and immunohistochemical characteristics for predicting the recurrence of medullary thyroid carcinoma. Ann Surg Oncol 17:2444–2451. https://doi.org/10.1245/s10434-010-1021-4
Franc B, Rosenberg-Bourgin M, Caillou B, Dutrieux-Berger N, Floquet J, Houcke-Lecomte M, Justrabo E, Lange F, Labat-Moleur F, Le Bodic MF, Patey M, Beauchet A, Saint-André JP, Hejblum G, Viennet G (1998) Medullary thyroid carcinoma: Search for histological predictors of survival (109 proband cases analysis). Hum Pathol 29:1078–1084. https://doi.org/10.1016/S0046-8177(98)90417-8
CAS Article PubMed Google Scholar
Raue F, Kotzerke J, Reinwein D, Schröder S, Röher HD, Deckart H, Höfer R, Ritter M, Seif F, Buhr H (1993) Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Investig 71:7–12 . https://doi.org/10.1007/BF00210956
CAS Article PubMed Google Scholar
Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L (1996) Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 77:1556–65.
Mian C, Pennelli G, Barollo S, Cavedon E, Nacamulli D, Vianello F, Negro I, Pozza G, Boschin IM, Pelizzo MR, Rugge M, Mantero F, Girelli ME, Opocher G (2011) Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: A useful tool for patient risk stratification. Eur J Endocrinol 164:971–976. https://doi.org/10.1530/EJE-11-0079
CAS Article PubMed Google Scholar
Pezzani R, Bertazza L, Cavedon E, Censi S, Manso J, Watutantrige-Fernando S, Pennelli G, Galuppini F, Barollo S, Mian C (2019) Novel Prognostic Factors Associated with Cell Cycle Control in Sporadic Medullary Thyroid Cancer Patients. Int J Endocrinol 2019. https://doi.org/10.1155/2019/9421079
Article PubMed PubMed Central Google Scholar
Tisell LE, Oden A, Muth A, Altiparmak G, Mõlne J, Ahlman H, Nilsson O (2003) The Ki67 index a prognostic marker in medullary thyroid carcinoma. Br J Cancer 89:2093–2097. https://doi.org/10.1038/sj.bjc.6601453
CAS Article PubMed PubMed Central Google Scholar
Fuchs TL, Nassour AJ, Glover A, Sywak MS, Sidhu SB, Delbridge LW, Clifton-Bligh RJ, Gild ML, Tsang V, Robinson BG, Clarkson A, Sheen A, Sioson L, Chou A, Gill AJ (2020) A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis. Am J Surg Pathol 44:1419–1428. https://doi.org/10.1097/PAS.0000000000001505
Article PubMed PubMed Central Google Scholar
Alzumaili B, Xu B, Spanheimer PM, Tuttle RM, Sherman E, Katabi N, Dogan S, Ganly I, Untch BR, Ghossein RA (2020) Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome. Mod Pathol 33:1690–1701. https://doi.org/10.1038/s41379-020-0532-1
CAS Article PubMed PubMed Central Google Scholar
Xu B, Fuchs TL, Ahmadi S, Alghamdi M, Alzumaili B, Bani M-A, Baudin E, Chou A, De Leo A, Fagin JA, Ganly I, Glover A, Hartl D, Kanaan C, Khneisser P, Najdawi F, Nigam A, Papachristos A, Repaci A, Spanheimer PM, Solaroli E, Untch BR, Barletta JA, Tallini G, Al Ghuzlan A, Gill AJ, Ghossein RA (2022) International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma. J Clin Oncol 40:96–104 . https://doi.org/10.1200/jco.21.01329
Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, Papotti MG, Berruti A, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2019) Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol Off J Eur Soc Med Oncol 30:1856–1883.https://doi.org/10.1093/annonc/mdz400
Mahul B. Amin, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR (2017) AJCC cancer staging manual, 8th ed. Springer International Publishing, New York
Moura MM, Cavaco BM, Pinto AE, Domingues R, Santos JR, Cid MO, Bugalho MJ, Leite V (2009) Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 100:1777–1783. https://doi.org/10.1038/sj.bjc.6605056
CAS Article PubMed PubMed Central Google Scholar
Simbolo M, Mian C, Barollo S, Fassan M, Mafficini A, Neves D, Scardoni M, Pennelli G, Rugge M, Pelizzo MR, Cavedon E, Fugazzola L, Scarpa A (2014) High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas. Virchows Arch 465:73–78. https://doi.org/10.1007/s00428-014-1589-3
CAS Article PubMed Google Scholar
Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S, Cirello V, Bottici V, Marconcini G, Rosa PM, Borrello MG, Basolo F, Ugolini C, Materazzi G, Pinchera A, Elisei R (2013) Evidence of a low prevalence of ras mutations in a large medullary thyroid cancer series. Thyroid 23:50–57. https://doi.org/10.1089/thy.2012.0207
CAS Article PubMed Google Scholar
Najdawi F, Ahmadi S, Capelletti M, Dong F, Chau NG, Barletta JA (2021) Evaluation of grade in a genotyped cohort of sporadic medullary thyroid carcinomas. Histopathology 79:427–436. https://doi.org/10.1111/his.14370
Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME (2020) Efficacy of Selpercatinib in RET -Altered Thyroid Cancers. N Engl J Med 383:825–835 . https://doi.org/10.1056/nejmoa2005651
留言 (0)